



Friday 17 May 2024 12:30 - 13:30 CEST Hamburg Hall, Hub27, Berlin, Germany

Please join our panel of experts for an engaging and interactive discussion around the evolution of ADCs for the treatment of patients with HR positive breast cancer.

Our esteemed experts will review data supporting the use of HER2 and TROP2 directed ADCs that have received approvals for treatment of HR positive mBC. They will also discuss evolving data for new ADC agents, including ADCs with novel targets. Finally, the panel will explore the importance of individualizing patient treatment decisions and discuss the current gap in treatment options for patients who have ET resistant disease. These discussions will be followed by a live Q&A where you will have the opportunity to ask questions to our speakers. We look forward to you joining us at the symposium!



Professor Hope Rugo (Chair) University of California San Francisco, USA



Professor Rebecca Dent
National Cancer Center
Singapore,
Republic of Singapore



Dr Komal JhaveriMemorial Sloan Kettering
Cancer Center,
New York, USA

12:30 - 12:35	Welcome and introduction	Hope Rugo
12:35 - 12:50	DELIVER: Established ADCs for treatment of HR positive mBC	Rebecca Dent
12:50 - 13:05	ADVANCE: Emerging data for novel ADCs in HR positive mBC	Komal Jhaveri
13:05 - 13:15	CHALLENGE: Tailoring treatment for patients with HR positive mBC	Hope Rugo
13:15 - 13:25	Q&A	All speakers
13:25 - 13:30	Meeting close	Hope Rugo

ADC, antibody-drug conjugate; ET, endocrine therapy; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; mBC, metastatic breast cancer; TROP2, tumor-associated calcium signal transducer 2.

This symposium is intended for HCPs in attendance at ESMO Breast Cancer 2024 and may discuss agents and products in development. This Industry Satellite Symposium is organized and funded by Daiichi Sankyo. This Industry Satellite Symposium is not available to delegates from Japan.

©2024 Daiichi Sankyo Europe GmbH. GLM-GCS-1062-0110. 04/24

